Navigation Links
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Date:7/20/2009

PITTSBURGH, July 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.

Haloperidol Tablets are an antipsychotic typically used to reduce the symptoms of schizophrenia and uncontrollable tics and outbursts associated with Tourette syndrome. Haloperidol had total U.S. sales of approximately $21 million for the 12 months ending March 31 for the same strengths, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 119 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... , ... The 12th session of the Silicon Valley BioTalks will take place ... CA. This Bay Area biotech event will focus on “Setting Up Early Stage Clinical ... company Hallux, biopharma Apexigen, Contract Research Organization (CRO) Experien Group, and Electronic Data Capture ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We are very pleased to ... Advisors. “Brad brings significant experience advising healthcare provider clients throughout the country. As ... implementation of MACRA, we believe that continuing to add professionals with deep experience ...
(Date:5/25/2016)... ... 25, 2016 , ... The Georgia State University College of Law new building ... Design Commission. , The annual award recognizes projects, programs, individuals and organizations that have ... of its physical heritage and the balance between the old and the new. , ...
(Date:5/25/2016)... Marne, Michigan (PRWEB) , ... May 25, 2016 ... ... abuse located in Central Michigan, has produced another video highlighting one of the ... their Martial Arts class. Sensei Ed Taylor, a 5 th Degree Black Belt ...
(Date:5/25/2016)... ... 25, 2016 , ... According to an article published May 5th on The Daily ... their breath. In fact, it found that more than a third cited unappealing breath a ... by pungent foods or a failure to brush after meals, can typically be attributed to ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today ... co-development agreement with Therawis Diagnostics GmbH to develop and commercialize ... develop and market PITX2 as a marker to predict effectiveness ... cancer patients. "We are pleased to partner with ...
(Date:5/25/2016)...  According to Kalorama Information, the world market ... Though these are challenging times in the market, ... for companies that remain optimistic and seek innovation.  ... prospects medical device companies spend a higher percentage ... than do companies in other industries.  Also, in ...
(Date:5/25/2016)... CORAL SPRINGS, Florida , May 25, 2016 /PRNewswire/ ... Marijuana Business Conference & Expo earlier this month, the ... undeniable. As revenues continue to climb into the billions, ... to the newly released 4th Edition State of Legal ... New Frontier, a cannabis-focused data-analysis firm, much of the ...
Breaking Medicine Technology: